CohBar Announces Changes to its Board of Directors and R&D Leadership
December 17 2021 - 9:00AM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
developing mitochondria based therapeutics to treat chronic
diseases and extend healthy lifespan, today announced changes to
its Board of Directors, Scientific Advisory Board (SAB), and
R&D leadership.
CohBar’s founders Drs. Nir Barzilai, Pinchas
Cohen, and John Amatruda have transitioned from the company’s Board
of Directors to a reconstituted SAB. The SAB will be comprised of
experts in mitochondrial science and other disciplines, working
with CohBar’s leadership to advance its pipeline and Mito+
platform.
In addition, Ken Cundy, Ph.D. has resigned from his position as
Chief Scientific Officer, effective March 31, 2022, in order to
explore other opportunities. The company is pleased to announce the
appointment of Kent Grindstaff, Ph.D., as CohBar’s Senior Vice
President of Research, effective January 4, 2022. Dr. Grindstaff is
well-versed in the company’s science and programs as he previously
served for six years as the VP, Biology at CohBar.
“CohBar has progressed under the leadership of Dr. Cundy into a
clinical stage company with a recent positive readout in our
program for NASH and obesity. We thank Ken for his contributions to
CohBar and wish him success in his future endeavors,” said Dr.
Joseph Sarret, Chief Executive Officer. “I am pleased to welcome
Dr. Grindstaff back to CohBar. His extensive experience in cell
biology, biochemistry, and assay development will guide CohBar in
our continued evaluation and development of novel peptides for
important indications such as idiopathic pulmonary fibrosis
(IPF).”
Dr. Grindstaff rejoins the company from BioAge Labs, where he
was the Senior Vice President, Discovery Research. Earlier in his
career, Dr. Grindstaff was Vice President, Global Operations at
Solvo Biotechnology USA and Principal Investigator at XenoPort,
Inc. Dr. Grindstaff holds a B.A. in Biology from Knox College,
received his Ph.D. in Molecular Cell Biology and Biochemistry from
Washington University in St. Louis and completed his post-doctoral
fellowship in the Department of Molecular and Cellular Physiology
at Stanford University.
“We believe these changes best position the
company to deliver on the promise of our technology platform and
provide the most value for our stockholders,” stated David
Greenwood, Chairman of the Board. “We remain optimistic about the
potential of these mitochondrially encoded peptides and the impact
they may have on the lives of patients with unmet medical
needs.”
About CohBar
CohBar (NASDAQ: CWBR) is a clinical stage
biotechnology company focused on the research and development of
mitochondria based therapeutics, an emerging class of drugs for the
treatment of chronic and age-related diseases. Mitochondria based
therapeutics originate from the discovery by CohBar’s founders of a
novel group of naturally occurring peptide sequences within the
mitochondrial genome, some of which have been shown to have the
potential to regulate key processes in multiple systems and organs
in the body. To date, the company has discovered more than 100
mitochondrial derived peptides and generated over 1,000 analogs.
CohBar’s efforts focus on the development of these peptides into
therapeutics that offer the potential to address a broad range of
diseases associated with the underlying impact of mitochondrial
dysfunction. The company’s lead compound, CB4211, which is under
development for the treatment of NASH and obesity, recently
completed a successful Phase 1a/1b clinical trial. In addition,
CohBar has four preclinical programs, the most advanced of which is
CB5138-3, a peptide with broad anti-fibrotic and anti-inflammatory
properties. This program is currently in IND-enabling studies with
the goal of filing an IND and initiating a first-in-human study in
2022 with an initial indication of idiopathic pulmonary fibrosis.
The company also has a program in ARDS, including COVID-19
associated ARDS, as well as two peptide families with potential
utility in treating various forms of cancer.
For additional company information, please visit
www.cohbar.com.
Forward-Looking Statements
This news release contains forward-looking statements that are
not historical facts within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are based
only on our current beliefs, expectations and assumptions regarding
the future of our business, future plans and strategies,
projections, anticipated events and other future conditions. In
some cases you can identify these statements by forward-looking
words such as “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “could,” “should,” “would,” “project,”
“plan,” “expect,” “goal,” “seek,” “future,” “likely” or the
negative or plural of these words or similar expressions. Examples
of such forward-looking statements include but are not limited to
statements regarding anticipated therapeutic properties and
potential of our technology platform, mitochondrial peptide
analogs, MBTs and other potential therapies. You are cautioned that
such statements are not guarantees of future performance and that
actual results or developments may differ materially from those set
forth in these forward-looking statements. Factors that could cause
actual results to differ materially from these forward-looking
statements include: our ability to successfully advance drug
discovery and development programs, including the delay or
termination of ongoing clinical trials and the timing of
announcements and updates relating to our clinical trials and
related data; our possible inability to mitigate the prevalence
and/or persistence of the injection site reactions, receipt of
unfavorable feedback from regulators regarding the safety or
tolerability of CB4211 or the possibility of other developments
affecting the viability of CB4211 or CB5138-3 as a clinical
candidate or its commercial potential; results that are different
from earlier data results including less favorable results that may
not support further clinical development; our ability to raise
additional capital when necessary to continue our operations; our
ability to recruit and retain key management and scientific
personnel; the risk that our intellectual property may not be
adequately protected; our ability to establish and maintain
partnerships with corporate and industry partners; and risks
related to the impact on our business of the COVID-19 pandemic or
similar public health crises. Additional assumptions, risks and
uncertainties are described in detail in our registration
statements, reports and other filings with the Securities and
Exchange Commission and applicable Canadian securities regulators,
which are available on our website, and at www.sec.gov
or www.sedar.com.
You are cautioned that such statements are not
guarantees of future performance and that our actual results may
differ materially from those set forth in the forward-looking
statements. The forward-looking statements and other information
contained in this news release are made as of the date hereof and
CohBar does not undertake any obligation to update publicly or
revise any forward-looking statements or information, whether as a
result of new information, future events or otherwise, unless so
required by applicable securities laws. Nothing herein shall
constitute an offer to sell or the solicitation of an offer to buy
any securities.
Contacts: Jordyn TaraziDirector of Investor
RelationsCohBar, Inc.(650)
445-4441Jordyn.tarazi@cohbar.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jun 2024 to Jul 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jul 2023 to Jul 2024